Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARQ 531 是一种可逆的、非共价的、具有口服活性的 BTK 抑制剂,能够作用于 WT-BTK (IC50:0.84 nM) 和 C481S-BTK (IC50:0.39 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 395 | 现货 | ||
2 mg | ¥ 567 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 3,490 | 现货 | ||
50 mg | ¥ 4,970 | 现货 | ||
100 mg | ¥ 7,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 983 | 现货 |
产品描述 | ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively. |
靶点活性 | BTK (WT):0.85 nM, BTK (C481S):0.39 nM |
体外活性 | In vitro treatment of patient CLL cells with ARQ 531 decreases BTK-mediated functions including B-cell receptor (BCR) signaling, viability, migration, CD40 and CD86 expression, and NF-κB gene transcription.?Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib[2]. |
体内活性 | In vivo, ARQ 531 was found to increase survival over ibrutinib in a murine Eμ-TCL1 engraftment model of CLL and a murine Eμ-MYC/TCL1 engraftment model resembling Richter transformation[2]. |
分子量 | 478.93 |
分子式 | C25H23ClN4O4 |
CAS No. | 2095393-15-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (104.40 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.088 mL | 10.4399 mL | 20.8799 mL | 52.1997 mL |
5 mM | 0.4176 mL | 2.088 mL | 4.176 mL | 10.4399 mL | |
10 mM | 0.2088 mL | 1.044 mL | 2.088 mL | 5.22 mL | |
20 mM | 0.1044 mL | 0.522 mL | 1.044 mL | 2.61 mL | |
50 mM | 0.0418 mL | 0.2088 mL | 0.4176 mL | 1.044 mL | |
100 mM | 0.0209 mL | 0.1044 mL | 0.2088 mL | 0.522 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ARQ 531 2095393-15-8 Angiogenesis Tyrosine Kinase/Adaptors BTK Btk MK1026 MK 1026 ARQ-531 Inhibitor inhibit ARQ531 Bruton tyrosine kinase MK-1026 inhibitor